Drug Development
44 articles on Drug Development, researched and written by the Shotlee Editorial Team from primary sources.
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.
7 min read
Beyond Weight Loss: The Next Wave of GLP-1 Drugs
The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.
7 min read
Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.
7 min read
Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss
A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.
7 min read
Ozempic & Wegovy: Unlocking the Brain's Fading Appetite Signals
A groundbreaking study reveals that the effectiveness of semaglutide, the active ingredient in popular weight loss medications like Ozempic and Wegovy, may be linked to the duration and intensity of chemical signals within specific brain cells. This research sheds light on why weight loss can plateau and offers clues for developing more sustained and effective future therapies.
6 min read
AI Startup Acquires Parkinson's Cell Therapy from Ozempic Maker
Mark Zuckerberg-backed AI startup Cellular Intelligence has acquired global rights to STEM-PD, an experimental Parkinson's disease cell therapy developed by Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy. This strategic move signals a new era for AI in accelerating complex therapeutic development.
7 min read
Antimicrobial Peptides: A New Link to Neurodegenerative and Amyloid Diseases
Discover the groundbreaking research linking antimicrobial peptides (AMPs) to neurodegenerative and amyloid diseases. This article delves into the shared mechanisms, bidirectional feedback loops, and potential new therapeutic strategies emerging from this exciting field.
8 min read
Unexpected Discoveries: How Failed Drugs Became Medical Breakthroughs
Discover how serendipity and keen observation transformed drug development, leading to life-changing treatments for conditions ranging from diabetes and obesity to erectile dysfunction and wrinkles.
6 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.
7 min read
Dr. Reddy's Semaglutide Inches Closer to Canadian Market Approval
Dr. Reddy's Laboratories has announced a significant milestone in its pursuit of bringing its semaglutide injection to the Canadian market, having received Drug Identification Numbers (DINs) from Health Canada. This development signals progress in the regulatory review process and underscores the company's commitment to expanding access to this important medication.
7 min read
China's Pharma Dominance Is Just Beginning
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
5 min read
Wasps and Frogs Evolve Bradykinin-Like Peptides Independently to Deter Predators
Researchers at The University of Queensland have uncovered how wasps and frogs produce bradykinin-like peptides that evolved separately from vertebrate versions to trigger pain in predators. These 'evolutionary doppelgängers' derive from toxin genes, overturning decades of scientific assumptions. This discovery highlights convergent evolution in animal defenses.
5 min read
Wegovy Data Challenges Foundayo, Resets Novo Valuation Debate
Novo Nordisk released new cross-trial data showing its oral Wegovy pill delivers greater weight loss than Eli Lilly's newly FDA-approved Foundayo obesity pill. With fewer adverse events and strong patient preference for Wegovy, this first direct comparison challenges Foundayo's profile. The findings arrive amid volatile CPSE:NOVO B stock performance, resetting valuation debates.
5 min read
Eli Lilly Turns to AI After GLP-1 Boom for Next Growth
Eli Lilly is leveraging artificial intelligence to find its next big breakthrough after the GLP-1 boom transformed diabetes and obesity treatment. With rivals like Novo Nordisk in hot pursuit, Lilly's AI investments promise faster drug discovery and smarter clinical trials. This strategic shift could diversify revenue and bring new options to patients sooner.
6 min read
Kailera Therapeutics Eyes IPO for Obesity Drug Pipeline
Boston-based Kailera Therapeutics is gearing up for an IPO to fuel its obesity drug pipeline, including Phase III GLP-1/GIP agonist ribupatide. Backed by $400M Series A and $600M Series B, the company eyes superior profiles versus blockbusters like Zepbound. Despite $368.7M deficits, topline data looms large.
5 min read
Mounjaro Maker Signs $2.7B AI Drug Research Deal
Eli Lilly, the maker of blockbuster GLP-1 drug Mounjaro, has signed a landmark $2.7 billion deal with AI drug discovery firm Insilico Medicine. This agreement builds on their 2023 software licensing pact and harnesses Insilico's AI engine to fast-track novel therapeutics across multiple areas. Patients and investors are watching closely for impacts on metabolic health innovations.
5 min read
GLP-1 Therapies: Risks and Rewards Across Conditions
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
5 min read
How Gila Monster Venom Led Scientists to Ozempic
A venomous desert lizard, the Gila monster, holds a surprising key to one of medicine's biggest breakthroughs: Ozempic. Its venom revealed exendin-4, a stable GLP-1 mimic that paved the way for transformative diabetes therapies. This unlikely origin story highlights nature's role in modern metabolic health.
5 min read
The Quest for Oral GLP-1s: History and Innovations
For decades, GLP-1 receptor agonists like Ozempic have transformed diabetes and obesity treatment via injections, but patients crave oral options. This guide traces the scientific quest for oral GLP-1s, from early discoveries and Gila monster breakthroughs to Rybelsus challenges and promising algae-based innovations. Understand the barriers and what's next for affordable, pill-based metabolic health.
5 min read
GLP-1, Muscle Weakness & Obesity Care: Dr. Bob's Insights
As GLP-1 drugs like Ozempic revolutionize obesity and diabetes care, muscle weakness emerges as a key challenge. Dr. Bob reveals why 47-65% discontinue treatment, patient perceptions vs. reality, and proven strategies like protein intake and strength training. Explore the next frontier in preserving muscle for long-term health.
4 min read
How Eli Lilly Used AI to Boost Zepbound & Mounjaro Production
While AI hype focuses on drug discovery, Eli Lilly has quietly used it to supercharge manufacturing of its blockbuster GLP-1s, Zepbound and Mounjaro. This led to record production volumes that avoided FDA shortages and fueled massive revenue growth. Here's how they did it with digital twins and defect detection tech.
7 min read
Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years
Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.
5 min read
$3,000 Minipigs Powering Europe's Drug Pipeline
In eastern Denmark, Ellegaard Gottingen Minipigs A/S breeds specialized $3,000 minipigs vital to Europe's drug pipeline, including Novo Nordisk's Ozempic and Wegovy. These biosecure facilities address supply chain vulnerabilities exposed by the pandemic's monkey shortages. As the EU pushes for biotech independence, these smaller, human-like pigs offer a strategic alternative.
6 min read
Best-Selling Drugs in the US: 2024 Sales Ranking
In 2024, the US pharmaceutical market crowned Keytruda (Merck & Co.) as the top-selling drug with $17.87 billion in revenue, according to Statista's 'Top pharmaceutical drugs' report. Oncology treatments like Keytruda lead, followed by diabetes heavyweights Ozempic and Mounjaro. This ranking underscores the shift toward biologics for cancer, diabetes, and autoimmune diseases.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
South Africa's 2026 Agenda Spotlights GLP-1 Obesity Drugs
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
4 min read
Ozempic Book Reframes Obesity Views in GLP-1 Era
A new book, 'Off the Scales,' reveals how Ozempic and GLP-1 drugs are reshaping societal views on obesity. Author Aimee Donnellan details their development, profound weight loss effects, and the urgent need for medical approaches to this growing crisis. Learn why these therapies mark a turning point in weight management.
2 min read
Novo Nordisk official notes substantial enthusiasm for Wegovy weight reduction pill
A Novo Nordisk official has highlighted significant interest in the company's Wegovy oral weight-loss tablet. The pill, launched recently, offers similar results to the injectable version at a more affordable price. It also provides secondary benefits for heart health.
3 min read
FDA Approvals for 2025
In 2025, the FDA approved 46 novel therapeutic agents from its Center for Drug Evaluation and Research, marking a slight dip from the five-year average but remaining above historical norms. Cancer led approvals, with advancements in modalities like kinase inhibitors and gene therapies. The year also introduced new programs and faced staffing challenges under changing leadership.
13 min read
Novo Nordisk's Extended Strategy with Weight Loss Medications Fuels Scientific Enthusiasm, Though Wall Street Remains Uneasy
Novo Nordisk has faced challenges with its stock and leadership due to the weight loss drug market. While scientists see potential in GLP-1 medications expanding beyond diabetes and obesity, investors are losing patience. Ongoing research highlights additional benefits like reducing cravings and aiding brain functions.
3 min read
GLP-1 Pills Are Coming: What You Should Know
Drug manufacturers are creating oral GLP-1 medications for obesity management. Injectable GLP-1 drugs like Ozempic have limitations, but pill versions offer a new option. One Wegovy pill is anticipated to receive FDA approval this year.
1 min read
Eli Lilly's Stock Momentum Builds Amidst Positive Clinical Data and Institutional Backing
Eli Lilly & Co. is experiencing heightened market interest, fueled by significant institutional investor activity and promising clinical data. The convergence of these factors raises questions about the sustainability of the company's valuation in light of high expectations.
4 min read
Peptide Therapeutics Market to Hit USD 82.19 Billion by 2032 Amid Rising Demand for Oncology Medicines: SNS Insider
The global Peptide Therapeutics Market is experiencing substantial growth, projected to reach USD 82.19 billion by 2032. This expansion is fueled by the increasing need for specialized medications, particularly in oncology and metabolic diseases. The U.S. market is expected to reach USD 35.71 billion by 2032.
4 min read
Dr. Reddy's Semaglutide Expectations Hinged on Prompt Approvals
Dr. Reddy's Laboratories (DRL) is banking on semaglutide for future revenue, but faces challenges in securing timely approvals. The company aims to launch the drug domestically after patent expiration, while also navigating international regulatory hurdles.
2 min read
Optum Rx: Why Payers Should Monitor These 3 Pipeline Medications
A new Optum Rx report identifies three drugs targeting chronic conditions that are under review by the FDA. The medications address significant cost drivers for payers, including weight management and chronic inflammatory conditions.
4 min read
Ozempic 2.0 is Coming: A Potentially More Transformative Treatment
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
7 min read
Peptide CDMO 2.0 Market Outlook to 2034: Emphasizing Integrated and Tech-Forward CDMOs
The global peptide CDMO 2.0 market is poised for substantial growth, driven by increasing demand for peptide therapeutics and advancements in manufacturing technologies. This growth is fueled by the need for flexible, scalable, and efficient peptide production to meet the demands of both established pharmaceutical companies and emerging biotechs.
6 min read
Pfizer Clinches $10B Acquisition of Obesity Drug Firm Metsera After Bidding War
Pfizer has successfully acquired Metsera, a company specializing in obesity drug development, for $10 billion, prevailing over Novo Nordisk in a competitive bidding process. This acquisition marks Pfizer's entry into the expanding obesity drug market. Metsera's treatments are still several years from regulatory approval.
3 min read
Lilly's Eloralintide Obesity Drug Advances to Phase 3 Trials
Eli Lilly is progressing its experimental amylin obesity drug, eloralintide, into late-stage clinical trials following successful phase 2 study outcomes. The mid-stage study demonstrated significant weight loss in participants receiving the highest dose of the drug.
3 min read
Novo Nordisk Shakeup: What Does This Mean for Wegovy & Weight Loss?
Novo Nordisk, the maker of Wegovy, is experiencing significant boardroom changes. This shakeup raises questions about the future of Wegovy, GLP-1 therapies, and the broader weight loss landscape. Let's delve into what this means for consumers and the future of metabolic health.
3 min read
Sinapic Acid: A Natural Boost for Diabetic Wound Healing?
Researchers at Nagaland University have identified Sinapic acid, a naturally occurring plant compound, as a potential therapeutic agent for diabetic wound healing. This discovery could lead to more effective and accessible treatments for diabetic foot ulcers.
3 min read
Revolutionizing Drug Discovery: AI and Peptide Therapy for Longevity
Artificial intelligence is revolutionizing the field of peptide therapy, drastically accelerating drug discovery timelines. This is especially promising for tackling complex diseases like Alzheimer's and advancing the field of longevity research.
3 min read